

# Sebastian Scholl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8566562/publications.pdf>

Version: 2024-02-01

40  
papers

744  
citations

623734  
14  
h-index

552781  
26  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1249  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1569-1583.	2.5	3
2	Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1481-1492.	2.5	1
3	Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2539-2548.	2.5	2
4	Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3191-3202.	2.5	14
5	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Advances, 2021, 5, 3279-3289.	5.2	21
6	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study. Blood, 2021, 138, 244-244.	1.4	60
7	Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. Cells, 2020, 9, 2493.	4.1	49
8	Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial. Blood, 2020, 136, 1-3.	1.4	4
9	Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia. Haematologica, 2017, 102, e129-e131.	3.5	19
10	Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Journal of Cancer Research and Clinical Oncology, 2017, 143, 337-345.	2.5	17
11	Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0150632.	2.5	34
12	Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2603-2610.	2.5	7
13	Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis. Annals of Hematology, 2016, 95, 1899-1901.	1.8	5
14	Detection of Enterococcus spp. in bronchoalveolar lavage fluid of patients with high-risk neutropenia: May it be ignored?. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1133-1136.	2.5	0
15	Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study. Blood, 2016, 128, 1066-1066.	1.4	5
16	Results of the Randomized Phase II Study Decider (AMLSC 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. Blood, 2016, 128, 589-589.	1.4	11
17	Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1661-1668.	2.5	10
18	Lower gastrointestinal bleeding in a patient with Crohn's disease and plasma cell leukemia in remission. Annals of Hematology, 2015, 94, 2063-2065.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Different clones of acute leukemia after successful treatment of Hodgkin's disease. <i>Annals of Hematology</i> , 2014, 93, 2077-2079.	1.8	0
20	Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1391-1397.	2.5	5
21	Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO). <i>Blood</i> , 2014, 124, 280-280.	1.4	8
22	Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. <i>Annals of Hematology</i> , 2013, 92, 1071-1077.	1.8	14
23	Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1397-1404.	2.5	13
24	The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 605-615.	2.5	9
25	The E3 ubiquitin ligase TRAF2 can contribute to TNF- $\alpha$ resistance in FLT3-ITD-positive AML cells. <i>Leukemia Research</i> , 2013, 37, 1557-1564.	0.8	10
26	Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm – Combined Prospective Analysis by the German AML Intergroup. <i>Journal of Clinical Oncology</i> , 2012, 30, 3604-3610.	1.6	121
27	Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory FLT3-ITD/691L mutation. <i>British Journal of Haematology</i> , 2012, 157, 483-492.	2.5	46
28	Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1293-1300.	2.5	15
29	Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. <i>Annals of Hematology</i> , 2011, 90, 473-475.	1.8	10
30	Clinical implications of molecular genetic aberrations in acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 491-505.	2.5	31
31	Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase $\beta$ . <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 861-872.	2.5	11
32	Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 years with acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2008, 80, 208-215.	2.2	70
33	Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations. <i>Leukemia and Lymphoma</i> , 2007, 48, 2418-2423.	1.3	4
34	Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia. <i>Annals of Hematology</i> , 2007, 86, 763-765.	1.8	6
35	Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia. <i>Leukemia Research</i> , 2005, 29, 849-853.	0.8	31
36	Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. <i>Transfusion</i> , 2005, 45, 1676-1683.	1.6	24

#	ARTICLE	IF	CITATIONS
37	Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. Translational Research, 2005, 145, 295-304.	2.3	24
38	Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2005, 131, 279-283.	2.5	7
39	Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells. Journal of Cancer Research and Clinical Oncology, 2004, 130, 711-718.	2.5	5
40	Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2004, 130, 704-710.	2.5	16